Optimal activated clotting time during peripheral artery endovascular procedures: cutting the gordian knot

被引:4
作者
Patrone, Lorenzo [1 ]
Pasqui, Edoardo [2 ]
Sheahan, Kevin [3 ,4 ]
de Donato, Gianmarco [2 ]
Thulasidasan, Narayanan [3 ,4 ]
机构
[1] London North West Univ Healthcare NHS Trust, West London Vasc & Intervent Ctr, London, England
[2] Univ Siena, Dept Med Surg & Neurosci, Unit Vasc Surg, Siena, Italy
[3] Guys & St Thomas NHS Trust, Dept Intervent Radiol, London, England
[4] St Thomas Hosp, London, England
关键词
Endovascular procedures; Anticoagulants drugs; Peripheral arterial disease; HEPARIN; COAGULATION; OUTCOMES; SURGERY;
D O I
10.23736/S0021-9509.23.12703-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
All endovascular procedures need an effective anticoagulation regimen that avoids thrombo-embolic complications due to the insertion and manipulation of various intravascular devices. Systemic heparinization reduces the risk of thrombosis but there is no conclusive evidence regarding the correct use of anticoagulant medications and accordant monitoring, especially in endovascular peripheral arterial procedures. An-ticoagulation must be maintained during the whole vascular procedure, especially during partial or complete blood flow interruption. Reaching and maintaining the correct coagulative status is mandatory to avoid or reduce thromboembolic complications that could limit the procedure's effectiveness or be harmful to the patient. Patients' baseline variables and procedure-related elements can influence the way anticoagulation should be administered and how coagulative status has to be monitored. This review aimed to clarify the critical points of anticoagulation and monitoring management for non-cardiac arterial procedures in order to understand the best way to manage vascular procedures anticoagulation.
引用
收藏
页码:240 / 246
页数:7
相关论文
共 50 条
  • [31] Clinical Outcomes of 5000 IU Heparin Versus Activated Clotting Time-Guided Heparinization During Noncardiac Arterial Procedures: A Propensity Score Matched Analysis
    Hoebink, Max
    Roosendaal, Liliane C.
    Beverloo, Marie-Jose
    Wiersema, Arno M.
    van der Ploeg, T.
    Steunenberg, Thomas A. H.
    Yeung, Kak Khee
    Jongkind, Vincent
    JOURNAL OF ENDOVASCULAR THERAPY, 2024,
  • [32] Defining Optimal Activated Clotting Time for Percutaneous Coronary Intervention: A Systematic Review and Bayesian Meta-Regression
    Mottillo, Salvatore
    Filion, Kristian B.
    Joseph, Lawrence
    Eisenberg, Mark J.
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2017, 89 (03) : 351 - 366
  • [33] Intravascular Ultrasound during Endovascular Intervention for Peripheral Artery Disease, by Severity, Location, Device, and Procedure
    Kumar, Ashish
    Shariff, Mariam
    Majmundar, Monil
    Stulak, John M.
    Anavekar, Nandan
    Deshmukh, Abhishek
    Bashir, Riyaz
    AMERICAN JOURNAL OF CARDIOLOGY, 2024, 225 : 41 - 51
  • [34] Ultrasonography for the optimal selection of patients suitable for single session arteriography and endovascular revascularization in severe peripheral artery disease
    Spinu, Mihail
    Gligor, Rares Ioan
    Olinic, Maria
    Homorodean, Calin
    Ober, Mihai Claudiu
    Tataru, Dan
    Sabiescu, Bogdan
    Onea, Laurentiu
    Achim, Alexandru
    Lazar, Leontin
    Olinic, Dan Mircea
    MEDICAL ULTRASONOGRAPHY, 2024, 26 (04) : 376 - 382
  • [35] Conversion From Activated Clotting Time to Anti-Xa Heparin Activity Assay for Heparin Monitoring During Extracorporeal Membrane Oxygenation*
    Villalba, Cristina A. Figueroa
    Brogan, Thomas, V
    McMullan, D. Michael
    Yalon, Larissa
    Jordan, D. Ian
    Chandler, Wayne L.
    CRITICAL CARE MEDICINE, 2020, 48 (12) : E1179 - E1184
  • [36] Safety of a single bolus administration of heparin without the measurement of activated clotting time during cryoballoon ablation: a prospective randomized controlled trial
    Shin, Dong Geum
    Lee, Minwoo
    Ahn, Jinhee
    Han, Sang-Jin
    Lim, Hong Euy
    JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY, 2023, 66 (02) : 463 - 470
  • [37] Comparison between activated clotting time and anti-activated factor X activity for the monitoring of unfractionated heparin therapy in patients with aortic aneurysm undergoing an endovascular procedure
    Dieplinger, Benjamin
    Egger, Margot
    Luft, Christian
    Hinterreiter, Franz
    Pernerstorfer, Thomas
    Haltmayer, Meinhard
    Mueller, Thomas
    JOURNAL OF VASCULAR SURGERY, 2018, 68 (02) : 400 - 407
  • [38] Direct Oral Anticoagulants Affect Activated Clotting Time During and Bleeding Events After Percutaneous Coronary Intervention
    Shibahashi, Eiji
    Abe, Takuro
    Kamishima, Kazuho
    Ebihara, Suguru
    Moriyama, Tetsu
    Shimazaki, Kensuke
    Saito, Katsumi
    Uchigata, Yasuko
    Jujo, Kentaro
    AMERICAN JOURNAL OF CARDIOLOGY, 2023, 204 : 1 - 8
  • [39] Weight Based Heparin Dosage with Activated Clotting Time Monitoring Leads to Adequate and Safe Anticoagulation in Non-Cardiac Arterial Procedures
    Doganer, Orkun
    Roosendaal, Liliane C.
    Wiersema, Arno M.
    Blankensteijn, Jan D.
    Yeung, Kak Khee
    Jongkind, Vincent
    ANNALS OF VASCULAR SURGERY, 2022, 84 : 327 - 335
  • [40] Impact of International Normalized Ratio and Activated Clotting Time on Unfractionated Heparin Dosing During Ablation of Atrial Fibrillation
    Hamam, Ismail
    Daoud, Emile G.
    Zhang, Jianying
    Kalbfleisch, Steven J.
    Augostini, Ralph
    Winner, Marshall
    Tsai, Shane
    Rhodes, Troy E.
    Houmsse, Mahmoud
    Liu, Zhenguo
    Love, Charles J.
    Tyler, Jaret
    Sachdev, Molly
    Weiss, Raul
    Hummel, John D.
    CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2013, 6 (03) : 491 - 496